KOO - From the response Bear received, 8 events per 100 man years would give them 240 events at 3600 man years. This could mean that 125 more patients would be required. One thing that could change the need for additional patients is rounding. Is 8 a rounded up or rounded down number. Another thing that could have an effect, time in the trial. We have now had patients on the drug for 120 weeks. If I recall correctly that is a little longer than was anticipated. If more patients are required it doesn't look like it will be to many, or for a very long time period. On its own this should be very good news and not very expensive for the company. Once the trial is fully enrolled to 2400 patients it adds approximately 500 man years per month. IMO there is nothing at all negative in this release as a short extention on the time and less than a couple of hundred patients is negligible in the grand scheme of things. Both of the things I mentioned previously could still happen and we should still have Top Line data before year end. The SSA will be a much better barometer.

All IMO, dyodd.

tada